Incyte (INCY) Misses Q3 EPS by 14c; Boosts FY15 Jakafi Net Revenue Outlook
Incyte (NASDAQ: INCY) reported Q3 EPS of ($0.22), $0.14 worse than the analyst estimate of ($0.08). Revenue for the quarter came in at $187.7 million versus the consensus estimate of $179.3 million.
The Company has updated its full year 2015 financial guidance, as detailed below.
| Previous Guidance | Updated Guidance | |||
| Jakafi net product revenues | $560-$575 million | $580-$590 million | ||
| Contract revenue (including milestone revenues) | $58 million | $78 million | ||
| Research and development expenses | $475-$500 million, includes non-cash stock compensation expense of $40-$45 million | Unchanged | ||
| Selling, general and administrative expenses | $195-$210 million, includes non-cash compensation expense of $30-$35 million | $200-$210 million, includes non-cash compensation expense of $30-$35 million |
For earnings history and earnings-related data on Incyte (INCY) click here.